A Strategic Roadmap for Developing and Commercializing Biosimilars
Biosimilars are expected to capture a significant share of the US biologics market in the next 5-10 years. For drug companies developing biosimilars, it is critical to address challenges in the areas of value proposition, competitive positioning, and market access for a successful launch.
The Biosimilars Opportunity
Drug patents for many biologics are set to expire within the next 10 years. In 2026 alone, the number of patent expirations will be almost twice the highest number for any previous year. These expirations coupled with the savings biosimilars are expected to offer against innovator treatments have primed the pharmaceutical market for significant biosimilars development.
To learn more about unique challenges facing biosimilars, sign up to receive our white paper when it is published.
About RxC International
We are a premier life sciences management consulting firm with deep expertise in Corporate Strategy, New Product Strategy, and Commercialization. We have significant strategic and operational expertise across the pharmaceutical landscape and have helped clients evaluate the biosimilars market, develop commercial strategies for biosimilars, and plan for life cycle optimization. We leverage our experience to apply best practices and proprietary frameworks to every client engagement.
To learn more about how we can help your biosimilar reach its full commercial potential, contact us.